Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Organogenesis Holdings (ORGO) over the last 10 years, with Q3 2025 value amounting to $3.1 million.

  • Organogenesis Holdings' Cash from Operations fell 6458.88% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.8 million, marking a year-over-year decrease of 37938.06%. This contributed to the annual value of $14.2 million for FY2024, which is 5404.47% down from last year.
  • Organogenesis Holdings' Cash from Operations amounted to $3.1 million in Q3 2025, which was down 6458.88% from -$32.9 million recorded in Q2 2025.
  • Organogenesis Holdings' Cash from Operations' 5-year high stood at $27.8 million during Q3 2021, with a 5-year trough of -$32.9 million in Q2 2025.
  • For the 5-year period, Organogenesis Holdings' Cash from Operations averaged around $4.3 million, with its median value being $7.8 million (2022).
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 28725.23% in 2021, then crashed by 79381.6% in 2025.
  • Over the past 5 years, Organogenesis Holdings' Cash from Operations (Quarter) stood at $17.9 million in 2021, then crashed by 56.54% to $7.8 million in 2022, then soared by 36.08% to $10.6 million in 2023, then increased by 3.04% to $10.9 million in 2024, then crashed by 71.85% to $3.1 million in 2025.
  • Its Cash from Operations stands at $3.1 million for Q3 2025, versus -$32.9 million for Q2 2025 and -$19.9 million for Q1 2025.